PV Bulletin

SAHPRA Consultation on Transition to VigiFlow Platform

SAHPRA invites HCRs and CROs to adapt to a new electronic reporting system for safety data.

Primary source: Redirecting

PV Impact Brief

Urgency: HighConfidence: high

What changed

Introduction of the VigiFlow platform as the mandatory electronic reporting portal for submitting adverse events (AEs) and serious adverse events (SAEs) in South Africa.

Why it matters

This transition to a fully digital reporting platform enhances the efficiency and accuracy of safety data submissions, aligning South Africa with international pharmacovigilance standards.

Action needed

Holders of Certificates of Registration and Clinical Research Organisations must update their safety databases and reporting workflows to comply with the new electronic reporting requirements for AEs and SAEs.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
ICSRCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Consultation
Policy status
consultation
Publication date
2026-07-22
Policy change
SAHPRA has launched a consultation on transitioning to the VigiFlow platform for electronic reporting of safety data. This initiative aims to digitalize pharmacovigilance and clinical trial safety reporting (ICSRs and SUSARs) in South Africa, aligning with international E2B standards.

Key changes

Introduction of VigiFlow as the primary electronic reporting portal; adoption of E2B reporting standards; updated technical specifications for submission of ICSRs from MAHs and SUSARs from clinical trial sponsors.

Affected workflows

ICSRCountry Compliance

Responsible groups

Pharmacovigilance OperationsIT / Database ManagementClinical Safety

PV impact

MAHs and clinical trial sponsors in South Africa will need to update their safety databases and reporting workflows to integrate with the VigiFlow platform. This represents a significant shift from current manual or paper-based processes to a fully digital E2B environment.

View regulator source

Source document details

Exact policy details

Document Number
PV02-2026/27
Applies to: Relevant to Holders of Certificates of Registration (HCRs) and Clinical Research Organisations (CROs)
Source text mentions 'Document Number: PV02-2026/27' · p. 1 · High · Source
Version
1
Applies to: Document version applicable for the consultation
Source text mentions 'Version: 1' · p. 1 · High · Source
Date Updated
22/07/2026
Applies to: Date of the latest update for the documentation
Source text mentions 'Date Updated: 22/07/2026' · p. 1 · High · Source
Consultation Meeting
Invitation for consultation
Applies to: Holders of Certificates of Registration and Clinical Research Organisations
Source text states 'invites all Holders of Certificates of Registration (HCRs) and Clinical Research Organisations (CROs) responsible for submitting adverse events...' · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 22, 2026

Full briefing

Practical implication

Holders of Certificates of Registration and Clinical Research Organisations must update their safety databases and reporting workflows to comply with the new electronic reporting requirements for AEs and SAEs.

The South African Health Products Regulatory Authority (SAHPRA) has initiated a consultation that requires all Holders of Certificates of Registration (HCRs) and Clinical Research Organisations (CROs) to transition to the VigiFlow platform for electronic safety reporting. This shift aims to modernize pharmacovigilance practices according to international E2B standards, necessitating updates to current manual reporting processes.

What changed: Introduction of the VigiFlow platform as the mandatory electronic reporting portal for submitting adverse events (AEs) and serious adverse events (SAEs) in South Africa.

Why it matters: This transition to a fully digital reporting platform enhances the efficiency and accuracy of safety data submissions, aligning South Africa with international pharmacovigilance standards.

Practical implication: Holders of Certificates of Registration and Clinical Research Organisations must update their safety databases and reporting workflows to comply with the new electronic reporting requirements for AEs and SAEs.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward